Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5273632
Max Phase: Preclinical
Molecular Formula: C57H66N14O14
Molecular Weight: 1171.24
Associated Items:
ID: ALA5273632
Max Phase: Preclinical
Molecular Formula: C57H66N14O14
Molecular Weight: 1171.24
Associated Items:
Canonical SMILES: NCC(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O
Standard InChI: InChI=1S/C57H66N14O14/c58-23-46(72)62-27-47(73)66-40(19-31-24-59-37-12-4-1-9-34(31)37)52(79)64-29-49(75)70-17-8-16-45(70)56(83)69-42(21-33-26-61-39-14-6-3-11-36(33)39)54(81)65-30-50(76)71-18-7-15-44(71)55(82)68-41(20-32-25-60-38-13-5-2-10-35(32)38)53(80)63-28-48(74)67-43(57(84)85)22-51(77)78/h1-6,9-14,24-26,40-45,59-61H,7-8,15-23,27-30,58H2,(H,62,72)(H,63,80)(H,64,79)(H,65,81)(H,66,73)(H,67,74)(H,68,82)(H,69,83)(H,77,78)(H,84,85)/t40-,41-,42-,43-,44-,45-/m0/s1
Standard InChI Key: YZHWEVKXHCYFES-RCWIFLETSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1171.24 | Molecular Weight (Monoisotopic): 1170.4883 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Cuffaro D, Ciccone L, Rossello A, Nuti E, Santamaria S.. (2022) Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition., 65 (20.0): [PMID:36250680] [10.1021/acs.jmedchem.2c01177] |
Source(1):